sodium cridanimod + megestrol acetate

This drug is a **combination therapy** composed of sodium cridanimod and megestrol acetate. **Sodium cridanimod** is a small molecule with immunomodulatory and potential antitumor properties under investigation, while **megestrol acetate** is a synthetic progestin used as an appetite stimulant and antineoplastic agent. This combination has been studied for its antitumor activity in women with recurrent or persistent endometrial carcinoma not amenable to surgery or radiotherapy, especially those who failed or are unsuitable for progestin monotherapy. The combination aims to utilize sodium cridanimod's immunomodulatory and possible antitumor effects alongside the hormonal (progestogenic and antigonadotropic) activity of megestrol acetate to control tumor growth and improve disease outcomes. The two drugs may have a pharmacological interaction, which has been the subject of pharmacokinetic studies in this combination context[1].